Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree Kano. At the same time, I am interested in learning everything I can about my investment. I have not heard anything that influences my position and at least I can say I made an educated choice.
I appreciate your efforts to share DD you found. I think it is important to look at everything. However, like GoingCoastal said, most longs are not bothered by it. It happens a lot and a 23% sale of 30 million shares does not concern me. You see, I am invested in this technology and I have no reason to believe it will not be successful. I am holding long here. It will take a lot more than that to have me concerned...
GLTU
I think you are right Pete. That is why doing your own DD is key. And when sharing new info, evidence should always be provided if it is intended to provide good info for others.
I can think of a lot of personal reasons for taking out some profit. I agree. I would not waste my time with a company of which I was highly suspicious. I have no reason to be concerned here. We have a great medical device in Cell-in-a-Box(R). It is worth the wait to see what trials tell us...
Thanks Pete. Once you get that, please share...
No one has a problem with the info here but we do like to manage by facts. We all Iike to see a link to anything mentioned especially for the first time. There may have been a story but it should be supported by a filing or something. We would like to see what you find, I always look for supporting evidence whether I make it known or not. I never just believe anything anyone here says. The Internet is rich with information. No need to take someone at their word.
Great post, Otsy. If it is true, there could be many reasons for it...
Thanks...
Thanks, can anyone else corroborate this? I don't have access to Bloomberg.
Nothing on the SEC website to support this information. How did you obtain this information? I certainly understand that it may be true and there is no telling the reason. However, putting out such information does need validation.
Please provide a link...
Thanks
Nuvilex gets honorable mention in Austranova's release regarding the opening of their new facility.
Austrianova Officialy Opens New Lab and GMP Facility in Thailand
Bangkok, December 4th 2014
Austrianova reports that it has officially opened its office, lab and GMP facility at Thailand Science Park, Bangkok. The opening ceremony, held last week, included scientific presentations and a site visit of the custom built facility. Attendees included representatives from the Thailand Science Park management, the Thai National Science and Technology Development Agency and the Thailand Center of Excellence for Life Sciences (TCELS) as well as guests of honour Kenneth L. Waggoner (CEO) and Gerald C. Crabtree (COO) of Nuvilex Inc.,and various other Austrianova partners and friends including the Austrian Trade Commission, Betagro, CDIP, Erber AG, Siricell, Mahidol University, King Mongkut’s University of Technology Thonburi and the team from Austrianova Singapore plus some key investors in Austrianova.
Brian Salmons, CEO of Austrianova, stated “As well as being pleased to officially open our Thai facility, we were happy to see so many friends and partners as well as various supporters of our endeavours. Our new facility includes a unique, state-of-the-art and custom-built, controlled environment isolator for cell production, which we believe to be the first in Asia. This isolator system, housed in a newly built conventional Class D cleanroom, will ensure that all Cell-in-a-Box® products are manufactured according to the highest international pharmaceutical production standards.”
Walter H. Gunzburg, Chairman of Austrianova, said “We have worked closely with TCELS to develop this world-first encapsulated cell production and research facility. This allows Austrianova to produce Cell-in-a-Box® encapsulated cell products for partners such as Nuvilex, Inc. as well as other key partners. We would like to thank all of our friends for making the opening ceremony such a great success.”
http://austrianova.com/december-4th-2014-austrianova-officialy-opens-new-lab-gmp-facility-thailand/
The opening of this facility is huge! I believe we needed this facility in order to start human trials for all CiaB's uses. This is very good news.
Nuvilex Announces the Opening of Austrianova's cGMP Live Cell Encapsulation Facility in Thailand
SILVER SPRING, Md., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that Nuvilex executives joined Thailand government officials at the grand opening of Austrianova's current Good Manufacturing Practices (cGMP) live-cell encapsulation facility within the Thai Science Park (TSP) in Bangkok, Thailand. The TSP is the premier Science, Technology and Innovation hub of Thailand and home to many leading international hi-tech and bio-tech companies.
Nuvilex contracted with its partner Austrianova to establish the manufacturing facility that will produce the Cell-in-a-Box(R) live-cell encapsulation product containing cancer prodrug-activating cells that will be used for the Phase 2b clinical trial of Nuvilex's pancreatic cancer treatment in Australia and for clinical trials in the United States related to the intractable pain associated with pancreatic cancer and the accumulation of malignant ascites fluid that results from late-stage pancreatic cancer and other abdominal cancers. This facility will also be used to encapsulate insulin-producing cells that will be pivotal for clinical trials of Nuvilex's treatment for insulin-dependent diabetes.
Nuvilex CEO and President, Kenneth L. Waggoner, stated, "Nuvilex is pleased that the new cGMP facility that will perform live cell encapsulation using the Cell-in-a-Box(R) encapsulation technology is officially open in Thailand. This is a vitally important event on the path to the new and later stage clinical trials for Nuvilex. We are pleased to have been invited as guest of honor at the grand opening ceremony and to have met with so many scientists and professors involved with the Cell-in-a-Box(R) technology."
Dr. Brian Salmons, CEO and President of Austrianova, commented, "We are proud to have opened our unique cGMP facility which utilizes the first state-of-the-art, custom-built, controlled gaseous environment isolator based cell production system in Asia. This isolator system, housed in a newly built conventional Class D cleanroom, will ensure that all Cell-in-a-Box(R) products are manufactured to the highest international pharmaceutical production standards."
Prof. Walter H. Gunzburg, Chief Scientific Officer of Nuvilex and Chairman of Austrianova, said, "Together with Thailand Center of Excellence in Life Sciences, we have worked for over a year to develop this world-first encapsulated cell production capability. Finally, through the close collaborative efforts of this Thai Government Agency with Austrianova and the Thailand Science Park, we have been able to achieve, in a remarkably short period, the realization of this unique facility."
To view pictures of the event and the new facility in the Thai Science Park, visit: http://www.nuvilex.com/index.php?option=com_eventgallery&view=event&layout=tiles&folder=Event1&Itemid=133
http://finance.yahoo.com/news/nuvilex-announces-opening-austrianovas-cgmp-143000606.html
That would be very nice efood... I expect him to be the one sharing the results. Wish I could have front row seats. :)
We should be hearing from him in the not too distant future regarding trial results. It makes sense that this study was his idea. As Ken W said, Nuvilex never intended to study CiaB's use for ascites. Von Hoff wanted to do this study and of course we obliged. Sounds like things went well too. But I am pretty sure Von Hoff will want the honors of delivering this news publicly. Just hurry up and wait now... :)
Dr Von Hoff DID contact Nuvilex.
In fact details about how the relationship began and the preclinicals can be heard starting @ 10:00 in the following interview from earlier this year.
http://www.stockmarketmediagroup.com/wp-content/uploads/2014/06/NVLX-CEO-COO-Interview.mp3
Very nice to see such a collaboration...
I agree. And now, two of the doctors that created this technology are on the Nuvilex team. I have no doubt that we are in good hands...
How does that prove your allegation? They are running a business and that takes money. I think the assumption that they are using it to pay for all that is going on, like exclusive rights to cannaboids is a more likely scenario given what we do know...
Alleging that instead they are just lining their pockets with shareholder money based on the fact that there is no revenue is illogical, IMO.
I don't believe that is true. It looks like a Cross Trade to me which would mean Chardan sold ours and then sold them to another of their clients. It certainly dropped the price but like I said, I am not planning on selling anytime soon so I will just ride the waves until we do get some more substantive news...
I like that we are raising money. It means things are happening...
That allegation cannot be substantiated for sure.
It's an investment philosophy that many have abandoned with the influx of traders and the use of the Internet. I still think it is good advise when you believe in the value of what you own. I and others here do believe in the value of Cell-in-a-Box(R)...
I am not going anywhere. I bought this stock because of Cell-in-a-Box(R) technology. We just heard good news regarding the recent preclinicals with Dr Von Hoff. We also just bought exclusive rights from Ausrianova for CiaB use with cannabanoids.
Again, the PPS here is not representative of what I own. It would be, however, if I did sell. But, I am holding out for what comes next. Like, ODD, Trial results, Phase 1, Phase 2, Diabetes, other uses with cannabinoids.
"The stock market remains an exceptionally efficient mechanism for the transfer of wealth from the impatient to the patient."
-- Warren Buffett
This could possibly be what happened on Friday if Chardan handled the transaction. It is called a Cross Trade.
"...cross trades are permitted in very selective situations such as when both the buyer and the seller are clients of the same asset manager. The portfolio manager can effectively "swap out" a bond or other fixed income product from one client to another and eliminate the spreads on both the bid and ask side of the trade. The broker and manager must prove a fair market price for the transaction and record the trade as a cross for proper regulatory classification.
The key point is that the asset manager must be able to prove to the SEC that the trade was beneficial to both parties before executing a cross trade."
http://www.investopedia.com/terms/c/crosstrade.asp
Nice, Setay. I think hearing ODD news next month is a real possibility and will certainly be a game changer...
Nice article...
Very well said bill. Yesterday's news is what we longs have been waiting to hear. Our confidence in this product is supported by the recent results. I, like you, like my position here and I am in no rush...
January 2015 Gastrointestinal Cancer Symposium Thanks efood...
Maybe Dr Von Hoff will present pre-clinical trial results at this event...
Gastrointestinal Cancers Symposium
2015 Gastrointestinal Cancers Symposium
The 2015 Gastrointestinal Cancer Symposium will be held from January 15-17, 2015 in San Francisco, California.
For detailed information on patient advocate opportunities, registration, and housing, visit www.gicasym.org. For additional questions, email patientadvocates@asco.org. Find out more about the symposium program and agenda, or view research abstracts from past meetings at www.asco.org/abstracts.
http://www.cancer.net/research-and-advocacy/patient-advocates/patient-advocate-programs-asco-symposia/gastrointestinal-cancers-symposium
Very interesting and helpful info.
Thanks
Honestly, I did expect trial result news to provide a bigger kicker. The results were positive but no full report and not presented to the medical community. We are still unknown to many. This news did not get everyone's full attention.
However, I think bull is right. This news will be presented to the medical community first and not in a PR. That is where we will start getting the attention of the right folks. Then to more trials and FDA approval... It is coming... My first biotech but I am learning, processes take time here. Lots of regulations...
For those of us who believe, we are not disheartened. It will move soon enough with all the positve things we have in play.
We should hear back from the EMA before year end and the EMA and FDA work together very well. This is also a technological device and not a drug.
Additionally, we recently applied in Australia.
But if you think that the FDA is the key, you probably do have a couple of months. I am always looking at this investment as one that could pop any day because it is such a promising technology and now it has been recently proven again.
We don't know what the results will actually tell us yet but it does sound like we may begin Phase I trials soon. If those go as well as it sounds like they went in preclinicals and with ODD approval, that may be the ticket to get this to pop. Who knows how long before this pops... But I believe the pop is imminent more than ever after today's news. :)
GLTU
Welcome highhertel. Here are some great links to get started.
http://www.stockmarketmediagroup.com/features/nvlx/
http://www.nuvilex.com/
Don't waste too much time, imo. If we get ODD approval from any one of three countries, this may really take off...
GLTU
Nuvilex shares preliminary trial results and it is all good! Very good news...
“The data itself is not only exciting from an ascites point of view, but also provides further evidence that encapsulated cells plus ifosfamide are effective at treating yet another type of malignant tumor. This provides the rationale for additional clinical trials of this novel therapy,” said Prof. Dr. Walter H. Günzburg, the Chief Scientific Officer of Nuvilex.
http://finance.yahoo.com/news/nuvilex-announces-preliminary-data-preclinical-143000084.html
We have been soooo waiting to hear that Cell-in-a-Box(R) technology is as good today as previously proven. Now we know that it is. Believers were right to believe. :)
The best part is the combo worked even better which sets us up for multiple partnerships, imo.
Yeah, that was a shocker. Scottrade said it was a feed error. I was a millionaire for a minute. :)
I appreciate your chart update. I do not read them so with what you just said in mind... It sure would be nice to get some good TD2 trial news or ODD approval to push this price over the 200dma. Also like to hear that sellers may be drying up. We have a lot of longs here, holding strong, waiting for some good news... :)
No word from Senior Cheif. Let's just keep him in our thoughts... He believed very strongly in CiaB treatment. Just wish it was available now for patients like him...
He said he had purchased them for his family. He is a long. I am sure he is still holding. Blessings to Senior Chief and his family.
Senior Cheif has been on my mind a lot lately. I do hope he and his family are well. Thanks for digging out this message from him...
Bull, this is very significant and really opens up the market for all abdominal cancers. What a breakthrough if Dr Von Hoff has found a treatment for ascites through Cell-in-a-Box(R) technology!
BTW, I must commend you on your excellent DD. Thank you... Here is to speedy FDA approval!
Breakthrough Diabetes Research to Be Commercialized by US-Based Nuvilex, Inc.
Australian research that has produced a line of insulin producing cells that could eliminate the need for injections for Type 1 diabetics will be commercialised by US company Nuvilex and its subsidiaries Nuvilex Australia and Nuvilex Europe.
The clinical-stage biotechnology company has obtained exclusive worldwide rights to use human insulin producing cells, termed "Melligen" cells, developed by UTS's Professor Ann Simpson and her colleagues.
In Type 1 or juvenile-onset diabetes the islet cells have been destroyed by an autoimmune disease.
Professor Simpson has been working over the past 20 years to develop the capacity of liver cells to take over the function of the pancreatic "islet" cells that normally produce insulin in the body and this agreement is a significant milestone for her work.
Professor Simpson began exploring the possibility activating liver cells to take up the role of the pancreas early in her research because of their similar makeup. "When a foetus develops, the liver and the pancreas form from the same endodermal origin," she said.
"I am pleased that after many years of diabetes research at UTS, Nuvilex will now be developing this technology for commercialisation to a global market," Professor Simpson said. "My team and I are excited by the prospect of working with Nuvilex to eliminate daily injections for insulin-dependent diabetic patients."
Nuvilex will undertake further study of Melligen cells with the goal of encapsulating them using the company's novel and proprietary Cell-in-a-Box® cellulose-based live cell technology. Animal testing will be undertaken to prove the encapsulated cells are capable of producing insulin "on demand" in diabetic animals.
Ultimately encapsulated Melligen cells will be placed into patients with Type 1 diabetes where it is hoped they will function as a form of "bio-artificial pancreas". In laboratory studies, Melligen cells have been shown to respond directly to the amount of glucose in their surroundings.
"This is a disease that affects millions of individuals around the world," said Nuvilex's CEO and President, Kenneth L. Waggoner." Some of the complications diabetics suffer from are eye disease, foot and leg problems, kidney disease and cardiovascular disease. These complications can be dangerous and even life-threatening.
"If we are successful, those afflicted with Type 1 diabetes will be freed from depending on daily insulin injections or the use of insulin pumps as well as the constant need to monitor their blood glucose levels and modify their diets."
The announcement of the Nuvilex agreement has coincided with the awarding of a National Health and Medical Research Council (NHMRC) grant to Professor Simpson for related work. Over the past 20 years she has received more than $7 million to advance research aimed at reversing Type 1 diabetes by using the liver as a surrogate system to produce insulin.
http://money.cnn.com/news/newsfeeds/articles/marketwire/11G025321-001.htm